The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) Study
Launched by NATIONAL UNIVERSITY OF SINGAPORE · Aug 10, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The SINGER Study is a research project aimed at finding out if certain lifestyle changes can help delay cognitive decline in older adults who are at risk for dementia. This study is based on earlier research from Finland that showed combining activities like exercise, healthy eating, brain training, and socializing can be beneficial. Over the next two years, participants in Singapore will be randomly assigned to either a group that receives these lifestyle interventions or a control group, helping researchers see if these changes can effectively support cognitive health.
To be eligible for the study, participants need to be between 60 and 77 years old, able to understand English or Chinese, and have a higher risk of dementia based on specific health factors. They should also have a score on a cognitive test that indicates they are experiencing some decline but are not severely impaired. Anyone with serious health issues, such as advanced dementia or major depression, would not be able to participate. Those who join can expect to engage in activities that promote physical and mental health, and they will be supported throughout the process to help them stay on track for the full duration of the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 60-77 years
- • Able to understand English/Chinese
- • Risk of dementia: Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) dementia risk score \>6 indicating the presence of modifiable risk factors Modifiable lifestyle factors (fulfilling at least one of the following LIBRA index for diet, cognitive activity, physical activity)
- • Cognitive performance at the mean level or slightly lower than expected for age (MoCA ≥18, ≤27)
- • No plans to travel outside of Singapore for an extended period of time over the course of the study
- • Free of physical disabilities that preclude participation in the study
- • Willing to complete all study-related activities for 24 months
- • Willing to be randomized to either lifestyle intervention group
- Exclusion Criteria:
- • malignant diseases
- • dementia
- • substantial cognitive decline (MoCA\<18)
- • major depression
- • symptomatic cardiovascular disease
- • revascularisation within 1 year
- • severe loss of vision, hearing or communicative ability
- • other conditions inhibiting from safe engagement in the prescribed intervention and other conditions preventing cooperation, as judged by the study physician
About National University Of Singapore
The National University of Singapore (NUS) is a leading global research university recognized for its commitment to advancing scientific knowledge and fostering innovation in healthcare. With a strong emphasis on interdisciplinary collaboration, NUS conducts cutting-edge clinical trials aimed at addressing critical health challenges and improving patient outcomes. The university's state-of-the-art facilities, coupled with its team of renowned researchers and clinicians, enable the development and evaluation of novel therapies and interventions. NUS is dedicated to translating research findings into practical applications, ultimately enhancing the quality of care and contributing to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Singapore, , Singapore
Singapore, , Singapore
Patients applied
Trial Officials
Christopher LH Chen, MD
Principal Investigator
National University of Singapore
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials